Clinical Edge Journal Scan

Real world tolerability of onabotulinum toxin A in chronic migraine


Key clinical point: The first two administrations of onabotulinum toxin A (onabotA) were well-tolerated in patients with chronic migraine, with adverse events (AE) being mostly mild and tolerability to onabotA not being correlated with AE or clinical response.

Major finding: The mean tolerability scores were 7.8/10 and 7.2/10 in the first and second onabotA administration sessions, respectively, with no association being observed between tolerability and AE occurrence or clinical response. The AE were mostly mild and were reported by 71.4% and 68.6% of patients after the first and second onabotA administration sessions, respectively; 49.5% of patients showed a 50% response rate between weeks 20 and 24.

Study details: This was an observational prospective cohort study including 105 patients with chronic migraine who had received onabotA for the first time.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: García-Azorín D et al. Real-world evaluation of the tolerability to onabotulinum toxin A: The RETO study. Toxins (Basel). 2022;14(12),850 (Dec 3). Doi: 10.3390/toxins14120850.

Recommended Reading

Evidence supporting atogepant as a promising treatment for migraine prevention
Migraine ICYMI
Alcohol as a trigger for migraine: What is the link?
Migraine ICYMI
Prior proton-pump inhibitor use ups migraine risk
Migraine ICYMI
Some patients with resistant chronic migraine may derive long-term benefits with erenumab
Migraine ICYMI
Migraine: Erenumab demonstrates superior efficacy over topiramate
Migraine ICYMI